Hyperphosphatemia is linked to increased mortality risk. Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate ...
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a ...
By 1970 the administration of aluminium hydroxide and/or calcium carbonate as phosphate binders in dialysis patients was virtually universal practice. In 1972, Alfrey was one of the first to ...
It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news ...
Hyperphosphatemia is linked to increased mortality risk. Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate ...
Hyperphosphatemia is linked to increased mortality risk. Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate ...
The review draws attention to the high non-adherence rates to phosphate binders, which are crucial in managing hyperphosphatemia in dialysis patients. Non-adherence rates range from 22% to 74% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback